A Two-part, Randomised, Open-label, Multicentre, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib Following Single 400 mg Doses of the Capsule Formulation in Patients With Advanced Solid Tumours
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 21 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 26 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov record.
- 26 Jun 2015 Planned End Date changed from 1 Apr 2015 to 1 Dec 2015 as reported ClinicalTrials.gov record.